Artur Oreziak

Warsaw, MZ, Poland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

Jugular implantation of a leadless ventricular pacemaker ten days after transfemoral leadless atrial pacemaker placement.

Jugular implantation of a leadless ventricular pacemaker ten days after transfemoral leadless atrial pacemaker placement.

Journal: Kardiologia polska
Published: May 22, 2026

The use of the bridge occlusion balloon as an anchor to remove a lost sheath during the transvenous lead extraction.

The use of the bridge occlusion balloon as an anchor to remove a lost sheath during the transvenous lead extraction.

Journal: Kardiologia polska
Published: April 28, 2026

Impact of Atrial and Dual-Chamber Leadless Pacing on Subcutaneous Implantable Cardioverter-Defibrillator Screening Eligibility.

Impact of Atrial and Dual-Chamber Leadless Pacing on Subcutaneous Implantable Cardioverter-Defibrillator Screening Eligibility.

Journal: Journal of cardiovascular electrophysiology
Published: April 07, 2026

Revisiting AAI pacing: Aveir AR leadless pacemaker implantation in heart transplanted patients and a practical qualification algorithm.

Revisiting AAI pacing: Aveir AR leadless pacemaker implantation in heart transplanted patients and a practical qualification algorithm.

Journal: Kardiologia polska
Published: March 12, 2026

Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM.

Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM.

Journal: European journal of heart failure
Published: February 18, 2026

Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy.

Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy.

Journal: Circulation
Published: September 22, 2025

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.

Journal: European heart journal
Published: July 30, 2025

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.

Journal: Journal of cardiac failure
Published: July 23, 2025

Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy.

Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy.

Journal: ESC heart failure
Published: April 23, 2025

Approaches to rate response and atrioventricular delay management in dual-chamber pacemaker programming: Insights from a retrospective multicenter study.

Approaches to rate response and atrioventricular delay management in dual-chamber pacemaker programming: Insights from a retrospective multicenter study.

Journal: Kardiologia polska
Published: March 07, 2025

Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Journal: JACC. Heart failure
Published: February 25, 2025

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.

Journal: JACC. Heart failure
Published: January 06, 2025
Showing 1-12 of 62

Last Updated: 09/26/2026